All In Biotech

Drug Trial Radar · NCT07127770

A Study to Understand How the Body Processes [14C]PF-07104091 in Healthy Participants

A Phase 1, Open-label, Fixed Sequence, 2-period Study in Healthy Adult Male Participants to Assess the Mass Balance, Absolute Bioavailability, Fraction Absorbed, and Pharmacokinetics of [ 14C]PF-07104091

Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

Aug 28, 2025

Primary completion

Oct 8, 2025

Study completion Nov 7, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn how the body processes the study medicine PF-07104091. The study is seeking participants who are: \- Healthy male aged 18 to 65 years of age Participants in the study will receive 14C-labeled PF-07104091 by mouth after a meal. After 14 days, the participants will receive PF-07104091 by mouth (after a meal) followed by IV fusion (given directly into a vein) of microdose \[14C\]PF-07104091. The study will help understand how the body processes study medicine PF-07104091 and how the medicine is changed and removed from the body after you take it. This study will also help to understand how much PF-07104901 is taken up into the blood. Participants will remain in the study clinic for a maximum of 23 days and will have one follow-up contact.

Conditions

  • Healthy Adults

Interventions

  • PF-07104091Drug

    Cyclin-dependent kinase-2 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Total Radiocarbon (14c) excreted in urineTime frame: From Predose up to 14 days post dose of period 1 and 2
  2. Percentage of Total Radiocarbon (14c) excreted in fecesTime frame: From Predose up to 14 days post dose of period 1 (and if applicable for Period 2)
  3. Percentage of Total Radiocarbon (14c) excreted in vomitus (if applicable)Time frame: From Predose up to 14 days post dose of period 1 only
  4. Cumulative Percent Recovery of Total Radiocarbon (14C)Time frame: From Predose up to 14 days post dose of period 1 only
  5. Percentage of Metabolite Detected in Plasma After Oral Administration of PF-07104091Time frame: From Predose to 14 days post dose of period 1
  6. Percentage of Metabolite Detected in Urine After Oral Administration of PF-07104091Time frame: From Predose to 14 days post dose of period 1
  7. Percentage of Metabolite Detected in Feces After Oral Administration of PF-07104091Time frame: From Predose to 14 days post dose of period 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON

    Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.